The D2/3 dopamine receptor in pathological gambling: A positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride

Addiction

Volumn 108, Issue 5, 2013, Pages 953-963

  Boileau, Isabelle ^a,b   Payer, Doris ^a,b   Chugani, Bindiya ^c   Lobo, Daniela ^a,b,c   Behzadi, Arian ^a,b   Rusjan, Pablo M ^a   Houle, Sylvain ^a   Wilson, Alan A ^a   Warsh, Jerry ^a,b   Kish, Stephen J ^a,b,c   Zack, Martin ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

11C (+) PHNO; Dopamine; Pathological gambling; Positron emission tomography

Indexed keywords

CARBON; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; OXAZINE DERIVATIVE; RACLOPRIDE; DIAGNOSTIC AGENT;

ADDICTION; ADULT; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC USE; GAMBLING; HUMAN; MALE; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; SELF REPORT; YOUNG ADULT; ARTICLE; METHODOLOGY;

ADULT; BEHAVIOR, ADDICTIVE; BRAIN; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; DOPAMINE ANTAGONISTS; GAMBLING; HUMANS; MALE; MIDDLE AGED; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SELF REPORT; YOUNG ADULT;

EID: 84876416732     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12066     Document Type: Article

References (94)

1. American Psychiatric Association (APA). DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, revised. Washington, DC: APA; 2000.
2. Potenza M. N. Should addictive disorders include non-substance-related conditions? Addiction 2006; 101: 142-151.
3. Holden C. Psychiatry. Behavioral addictions debut in proposed DSM-V. Science [News] 2010; 327: 935.
4. Wise R. A., Rompre P. P. Brain dopamine and reward. Annu Rev Psychol 1989; 40: 191-225.
5. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 1995; 38: 95-137.
6. Nestler E. J., Malenka R. C. The addicted brain. Sci Am 2004; 290: 78-85.
7. da Silva Lobo D. S., Vallada H. P., Knight J., Martins S. S., Tavares H., Gentil V. etal. Dopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud 2007; 23: 421-433.
8. Comings D. E., Rosenthal R. J., Lesieur H. R., Rugle L. J., Muhleman D., Chiu C. etal. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996; 6: 223-234.
9. Lobo D. S., Kennedy J. L. The genetics of gambling and behavioral addictions. CNS Spectr 2006; 11: 931-939.
10. Lobo D. S., Souza R. P., Tong R. P., Casey D. M., Hodgins D. C., Smith G. J. etal. Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects. Biol Psychol 2010; 85: 33-37.
11. Bergh C., Eklund T., Sodersten P., Nordin C. Altered dopamine function in pathological gambling. Psychol Med 1997; 27: 473-475 [Research support, non-US Government].
12. Roy A., De Jong J., Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Arch Gen Psychiatry 1989; 46: 609-612.
13. Nordin C., Sjodin I. CSF cholecystokinin, gamma-aminobutyric acid and neuropeptide Y in pathological gamblers and healthy controls. J Neural Transm 2007; 114: 499-503.
14. Tremblay A. M., Desmond R. C., Poulos C. X., Zack M. Haloperidol modifies instrumental aspects of slot machine gambling in pathological gamblers and healthy controls. Addict Biol 2011; 16: 467-484.
15. Zack M., Poulos C. X. Parallel roles for dopamine in pathological gambling and psychostimulant addiction. Curr Drug Abuse Rev 2009; 2: 11-25.
16. Zack M., Poulos C. X. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology 2007; 32: 1678-1686.
17. Riba J., Kramer U. M., Heldmann M., Richter S., Munte T. F. Dopamine agonist increases risk taking but blunts reward-related brain activity. PLoS ONE 2008; 3: e2479.
18. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S. etal. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66: 1750-1752.
19. Dagher A., Robbins T. W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009; 61: 502-510.
20. Potenza M. N. Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Phil Trans R Soc Lond B Biol Sci 2008; 363: 3181-3189.
21. Reuter J., Raedler T., Rose M., Hand I., Glascher J., Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8: 147-148.
22. Linnet J., Moller A., Peterson E., Gjedde A., Doudet D. Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction 2011; 106: 383-390.
23. Linnet J., Moller A., Peterson E., Gjedde A., Doudet D. Inverse association between dopaminergic neurotransmission and Iowa Gambling Task performance in pathological gamblers and healthy controls. Scand J Psychol 2011; 52: 28-34.
24. Clark L., Stokes P. R., Wu K., Michalczuk R., Benecke A., Watson B. J. etal. Striatal dopamine D(2)/D(3) receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage 2012; 63: 40-46.
25. O'Sullivan S. S., Wu K., Politis M., Lawrence A. D., Evans A. H., Bose S. K. etal. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011; 134: 969-978.
26. Volkow N. D., Chang L., Wang G. J., Fowler J. S., Ding Y. S., Sedler M. etal. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001; 158: 2015-2021.
27. Martinez D., Saccone P. A., Liu F., Slifstein M., Orlowska D., Grassetti A. etal. Deficits in dopamine d(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biol Psychiatry 2012; 71: 192-198.
28. Martinez D., Broft A., Foltin R. W., Slifstein M., Hwang D. R., Huang Y. etal. Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 2004; 29: 1190-1202.
29. Martinez D., Gil R., Slifstein M., Hwang D. R., Huang Y., Perez A. etal. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005; 58(10): 779-786.
30. Lee B., London E. D., Poldrack R. A., Farahi J., Nacca A., Monterosso J. R. etal. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009; 29: 14734-14740.
31. Wang G. J., Volkow N. D., Fowler J. S., Logan J., Abumrad N. N., Hitzemann R. J. etal. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 1997; 16: 174-182.
32. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Hitzemann R. etal. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386: 830-833.
33. Volkow N. D., Fowler J. S., Wolf A. P., Schlyer D., Shiue C. Y., Alpert R. etal. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990; 147: 719-724.
34. Wang G. J., Smith L., Volkow N., Telang F., Logan J., Tomasi D. etal. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 2012 Sep; 17: 918-925.
35. Martinez D., Carpenter K. M., Liu F., Slifstein M., Broft A., Friedman A. C. etal. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry 2011; 168: 634-641.
36. Wang G. J., Volkow N. D., Thanos P. K., Fowler J. S. Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J Addict Dis 2004; 23: 39-53.
37. Kim S. H., Baik S. H., Park C. S., Kim S. J., Choi S. W., Kim S. E. Reduced striatal dopamine D2 receptors in people with Internet addiction. Neuroreport 2011; 22: 407-411.
38. Grace A. A. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 2000; 95: S119.
39. Noble E. P. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry 2000; 15: 79-89.
40. Volkow N. D., Fowler J. S., Wang G. J. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004; 47: 3-13.
41. Le Foll B., Diaz J., Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003; 47: 176-183.
42. Le Foll B., Schwartz J. C., Sokoloff P. Dopamine D3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 2000; 15: 140-146.
43. Heidbreder C. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. CNS Neurol Disord Drug Targets 2008; 7: 410-421.
44. Heidbreder C. A., Newman A. H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann NY Acad Sci 2010; 1187: 4-34.
45. Mash D. C., Staley J. K. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann NY Acad Sci 1999; 29: 507-522.
46. Segal D. M., Moraes C. T., Mash D. C. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 1997; 45: 335-339.
47. Staley J. K., Mash D. C. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996; 16: 6100-6106.
48. Boileau I., Payer D., Houle S., Behzadi A., Rusjan P. M., Tong J. etal. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 2012; 32: 1353-1359.
49. Cole D. M., Beckmann C. F., Searle G. E., Plisson C., Tziortzi A. C., Nichols T. E. etal. Orbitofrontal connectivity with resting-state networks is associated with midbrain dopamine D3 receptor availability. Cereb Cortex 2012 Dec; 22: 2784-2793.
50. Sokoloff P., Giros B., Martres M. P., Bouthenet M. L., Schwartz J. C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-151.
51. Murray A. M., Ryoo H. L., Gurevich E., Joyce J. N. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 1994; 91: 11271-11275.
52. Wilson A. A., McCormick P., Kapur S., Willeit M., Garcia A., Hussey D. etal. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3, 4, 4a, 5, 6, 10b-hexahydro-2H-naphtho[1, 2-b][1, 4]oxazin-9 -ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 2005; 48: 4153-4160.
53. Tziortzi A. C., Searle G. E., Tzimopoulou S., Salinas C., Beaver J. D., Jenkinson M. etal. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011; 54: 264-277.
54. Willeit M., Ginovart N., Kapur S., Houle S., Hussey D., Seeman P. etal. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [(11)C]-(+)-PHNO. Biol Psychiatry 2006 Mar 1; 59: 389-394.
55. Seeman P. Dopamine D2high receptors measured ex vivo are elevated in amphetamine-sensitized animals. Synapse 2009; 63: 186-192.
56. Narendran R., Martinez D., Mason N. S., Lopresti B. J., Himes M. L., Chen C. M. etal. Imaging of dopamine D(2/3) agonist binding in cocaine dependence: a [(11) C]NPA positron emission tomography study. Synapse 2011; 65: 1344-1349.
57. Beaudoin C. M., Cox B. J. Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire. Can J Psychiatry 1999; 44: 483-487.
58. Lesieur H. R., Klein R. Pathological gambling among high school students. Addict Behav 1987; 12: 129-135.
59. Stinchfield R. Reliability, validity, and classification accuracy of the South Oaks Gambling Screen (SOGS). Addict Behav 2002; 27: 1-19.
60. Strong D. R., Breen R. B., Lesieur H. R., Lejuez C. W. Using the Rasch model to evaluate the South Oaks Gambling Screen for use with nonpathological gamblers. Addict Behav 2003; 28: 1465-1472.
61. First M. B., Spitzer R. L., Gibbon M. Axis I disorders. New York: Biometrics Research Department, NY State Psychiatric Institute; 1995.
62. Beck A. T., Beck R. W. Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972; 52: 81-85.
63. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
64. Wechsler D. Manual for the Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1981.
65. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
66. Sanchez-Craig M., Wilkinson D. A., Davila R. Empirically based guidelines for moderate drinking: 1-year results from three studies with problem drinkers. Am J Public Health 1995; 85: 823-828.
67. Ross H. E., Gavin D. R., Skinner H. A. Diagnostic validity of the MAST and the alcohol dependence scale in the assessment of DSM-III alcohol disorders. J Stud Alcohol 1990; 51: 506-513.
68. Skinner H. A., Allen B. A. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 1982; 91: 199-209.
69. Skinner H. A. The drug abuse screening test. Addict Behav 1982; 7: 363-371.
70. Eysenck H. J., Eysenck S. B. Personality Structure and Measurement. San Diego, CA: Knapp; 1969.
71. Logan G. D., Schachar R. J., Tannock R. Impulsivity and inhibitory control. Psychol Sci 1997; 8: 60-64.
72. Fischman M. W., Foltin R. W. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991; 86: 1563-1570 [Review].
73. Shacham S. A shortened version of the Profile of Mood States. J Pers Assess 1983; 47: 305-306.
74. Graff-Guerrero A., Willeit M., Ginovart N., Mamo D., Mizrahi R., Rusjan P. etal. Brain region binding of the D(2/3) agonist [(11)C]-(+)-PHNO and the D(2/3) antagonist [(11)C]raclopride in healthy humans. Hum Brain Mapp 2008; 29: 400-410.
75. Rusjan P., Mamo D., Ginovart N., Hussey D., Vitcu I., Yasuno F. etal. An automated method for the extraction of regional data from PET images. Psychiatry Res 2006; 147: 79-89.
76. Rusjan P. Kinetics of [11C]-(+)-PHNO binding in the globus pallidus. Neuroimage 2008; 41: T137.
77. Innis R. B., Cunningham V. J., Delforge J., Fujita M., Gjedde A., Gunn R. N. etal. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
78. Lammertsma A. A., Hume S. P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-158.
79. Zack M., Poulos C. X. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology 2004; 29: 195-207.
80. Nower L., Derevensky J. L., Gupta R. The relationship of impulsivity, sensation seeking, coping, and substance use in youth gamblers. Psychol Addict Behav 2004; 18: 49-55.
81. Vitaro F., Wanner B. Predicting early gambling in children. Psychol Addict Behav 2011; 25: 118-126.
82. Dalley J. W., Fryer T. D., Brichard L., Robinson E. S., Theobald D. E., Laane K. etal. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007; 315: 1267-1270.
83. Buckholtz J. W., Treadway M. T., Cowan R. L., Woodward N. D., Li R., Ansari M. S. etal. Dopaminergic network differences in human impulsivity. Science 2010; 329: 532.
84. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Wong C. etal. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291: 409-415.
85. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Gifford A. etal. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999; 156: 1440-1443.
86. Thanos P. K., Volkow N. D., Freimuth P., Umegaki H., Ikari H., Roth G. etal. Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem 2001; 78: 1094-1103.
87. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J. C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997; 94: 3363-3367.
88. Seeman P., Tallerico T., Ko F., Tenn C., Kapur S. Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 2002; 46: 235-239.
89. Willeit M., Ginovart N., Graff A., Rusjan P., Vitcu I., Houle S. etal. First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: a [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 2008; 33: 279-289.
90. Shotbolt P., Tziortzi A. C., Searle G. E., Colasanti A., van der Aart J., Abanades S. etal. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 2012 Jan; 32(1): 127-136.
91. Dodd M. L., Klos K. J., Bower J. H., Geda Y. E., Josephs K. A., Ahlskog J. E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62: 1377-1381.
92. Haber S. N., Fudge J. L., McFarland N. R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 2000; 20: 2369-2382.
93. Lorains F. K., Cowlishaw S., Thomas S. A. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction 2011; 106: 490-498.
94. Boileau I., Guttman M., Rusjan P., Adams J. R., Houle S., Tong J. etal. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009; 132(Pt 5): 1366-1375.